CRDL Cardiol Therapeutics Inc.

TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · cardiolrx.com

1.970CAD-2.96%Mkt Cap: 179.64M $P/E: —Today

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx,…

Industry Peers

Drug Manufacturers - Specialty & Generic

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

$57.06BUSD

TEVA

Teva Pharmaceutical Industries Limited Ordinary Shares

$46.10BUSDP/E 65.9

HLN

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Zoetis Inc. Class A Common Stock

$28.80BUSDP/E 11.4

UTHR

United Therapeutics Corporation - Common Stock

$23.23BUSDP/E 19.4

VTRS

Viatris Inc. - Common Stock

$20.22BUSD

SOBI

Swedish Orphan Biovitrum AB

$14.24BUSDP/E 109.4

NBIX

Neurocrine Biosciences, Inc. - Common Stock

Elanco Animal Health Incorporated Common Stock

$11.06BUSD

RDY

Dr. Reddy's Laboratories Ltd Common Stock

Amneal Pharmaceuticals, Inc. - Class A Common Stock

$7.07BUSDP/E 42.3

ALKS

Alkermes plc - Ordinary Shares

$7.00BUSDP/E 109.9

HIMS

Hims & Hers Health, Inc. Class A Common Stock

$6.77BUSD

LNTH

Lantheus Holdings, Inc. - Common Stock

$6.53BUSDP/E 23.9

KNSA

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

$5.83BUSDP/E 76.6

INDV

Indivior Pharmaceuticals, Inc. - Common Stock

$4.21BUSDP/E 12.8

Key Statistics

Company

Market Cap179.64M USD

Enterprise Value153.79M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-24.63M USD

Revenue/Share—

Last Price1.970 CAD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees18

CountryCA

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-6.21

PEG—

EV/EBITDA-5.89

EV/Revenue—

P/S—

P/B9.81

EPS (TTM)-0.34

EPS (Forward)-0.33

52W Range

1.22537% of range3.230

52W High3.230 CAD

52W Low1.225 CAD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-189.17%

ROA-143.18%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-17.37M USD

CapEx (TTM)17.83K USD

FCF Margin—

FCF Yield-6.27%

Net Debt-18.92M USD

Net Debt/EBITDA0.72

Balance Sheet

Debt/Equity0.01

Current Ratio5.55

Quick Ratio5.01

Book Value/Sh0.21 CAD

Cash/Share0.22 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CAD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.3 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)6.000 CAD

Upside (mean)+204.6%

Target Range5.000 CAD – 7.000 CAD

5.000+204.6% to mean7.000

# Analysts2

Ownership

Shares Out.121.51M

Float91.98M

Insiders2.27%

Institutions26.40%

Short Interest

Short Ratio2.6d

Short % Float0.65%

Short % Out.0.63%

Shares Short765.66K

Short (prev mo.)172.46K

Technical

SMA 502.431 (-19.0%)

SMA 2001.785 (+10.4%)

Beta0.61

S&P 52W Chg14.58%

Avg Vol (30d)299.80K

Avg Vol (10d)230.60K

Technical Indicators

RSI (14)32.5

MACD-0.0459

MACD Signal0.0499

MACD Hist.-0.0958

BB Upper3.247 CAD

BB Middle2.639 CAD

BB Lower2.031 CAD

BB Width46.10%

ATR (14)0.1734 CAD

Vol Ratio (20d)2.13x